Talking about 1720, it is absolutely right that we have initiated a Phase III trial in Mastenagravis. The trial has initiated late last year. We expect to read out in a number of months. It’s obviously a field we know well. It’s a subcut formulation as you have emphasized and we have a big hope with this product. we will also study potentially other indications for this bispecific 1720 in the coming months. Talking about the synergies, it is a fact that we have been able to find quite a lot of synergies in manufacturing, in enabling functions but also synergies in the scientific world where we can — when Alexion can now tap into many of the existing capabilities in research and development and a lot of change of animal models or chemical library, high scope screening.
I mean, the variety of synergies is wide. And we do reinvest part of the synergies into beefing up our own research and development capabilities for us to develop more molecules. We expect to have by the end of 2023, about 10 products in Phase III trials. So far, this is a great increase in comparison to what we had in the past. And of course, we will provide when these products become ready for Phase III, we will provide visibility and explain what they are going to produce this.
Pascal Soriot: Thank you, Marc. Maybe add just some other color on Alexion. It is a very good company, a very strong company. It’s a very strong team, good science, good products. So essentially and then also very high profitability, as you know very well from past numbers that Alexion was publishing — so our goal is really not to try and optimize the cost base we’re generating a lot of cost synergies and we’re investing quite a bit of this in the pipeline because our goal is to drive the top line. If we drive the top line, mechanically, we will improve the operating margin of the overall AstraZeneca. So we’re really investing in the pipeline. We are investing in expanding the coverage globally in China, emerging markets, et cetera, et cetera.
That’s really the goal we have. Operating margin improvement as a percentage, they really have to come from other parts of the company. But for Alexion, it’s really a top line-driven focus. The next one is James Gordon, JPMorgan. James, over to you.
James Gordon: James Gordon, JPMorgan. I’ll try and restrain myself with a number of questions and just ask 2 about upcoming pipeline data points. The first one was on Dato-DXd and upcoming TL-1 data. So this data is in refractory lung — and assuming you do show a significant benefit versus chemo how should we extrapolate that to the TL07, TL08 and the Avanza trials that have been front line. Would we extrapolate just the absolute benefit on PFS OS? Or would it be the proportional benefit, the hazard ratio that we would extrapolate? That will be the first question, please. And then the second question, also upcoming, so you’ve got FLORA2data, Tagrisso and chemo. How confident are you that’s going to show a clinically meaningful benefit to justify extratox and extreme convenience from chemo?
And how do you think now that might stack up versus what J&J might show from our poster with their combo approach where we’re also going to get Phase III data at the end of this year?
Pascal Soriot: Susan, I think those are both for you.
